CSI Market
Sign In | Register

Immunic Inc (IMUX) Annual Cash Flow Statement

Annual · GAAP · USD millions
Access IMUX quarterly Cash Flow →
The cash flow figures below highlight longer-term patterns in how Immunic Inc manages cash inflows and outflows over time.
View historic periods: Download as CSV:
Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.
Annual Report, GAAP in USD millions
ITEM 		(Dec 31 2025)
12 Months 		(Dec 31 2024) (Dec 31 2023) (Dec 31 2022) (Dec 31 2021)
Operating Activities
Income-97.17
Depreciation & amortization0.17
Amortization of Other Assets0.00
Extraordinary Item, Gain (Loss), Insurance Assets, Accretion Expense0.00
Goodwill, Impairment Loss0.00
Provision For Loan Losses Expensed0.50
Inventories Decrease /-Increase0.00
R & D, Environmental and Other Expense0.00
Gain (Loss) on Disposition of Property Plant Equipment0.00
Share-based Compensation8.86
Income (Loss) from Equity Method Investments0.00
Foreign Currency Transaction Gain (Loss), before Tax, Total0.00
Gain Loss On Re Measurement Of Preferred Stock Warrant Liability-
Change In Fair Value Of Tranche Rights-
Gain Loss From Change In Fair Value Of Tranche Rights-
Increase Decrease In Operating Lease Liability-0.51
Income taxes0.00
Gain (Loss) on Sale of Equity Investments0.00
Accounts Receivable0.00
Increase (Decrease) in Accounts Payable1.24
Increase (Decrease) in Accrued Liabilities4.48
Deferred Revenue and Customer Advances and Deposits0.00
Increase (Decrease) in Prepaid Expense and Other Assets-3.16
Other Working Capital-0.21
Other Noncash Income (Expense)0.00
Other net0.00
Payments for (Proceeds from) Other Operating Activities0.00
Discontinued operations0.00
Net Cash flow from Operating Activities-85.81
Investing Activities
Capital Expenditures-0.16
Sale of Capital Items0.00
Payments for (Proceeds from) Investments0.00
Short-term Investments Acq.0.00
Real Estate Investments0.00
Cash Acquired In Connection With Reverse Acquisition-
Increase (Decrease) in Restricted Cash0.00
Payments for (Proceeds from) Loans0.00
Payments for (Proceeds from) Deposits0.00
Proceeds from Sale of Other Investments0.00
Payments for (Proceeds from) Federal Reserve and FHLB0.00
Acquisition Net of Cash Acquired0.00
Interest in Subsidiaries and Affiliates0.00
Sale of businesses0.00
Accounts payable0.00
Receivables0.00
Payments for (Proceeds from) Other Investing Activities0.00
Other Net0.00
Discontinued operations0.00
Net Cash Flow from Investing Activities-0.16
Financing Activities
Short-term debt Net0.00
Other borrowing transactions0.00
Long-term debt - borrowings0.00
Long-term debt - repayments0.00
Federal Home Loan Bank and Federal Funds0.00
Issuances / -repurchases of Comm. Stock0.18
Partnership and Parent Transactions0.00
Issuances / -repurchases of Pref. Stock0.00
Deposits, Annuities, Contract Holders Funds0.00
Other financing activities net0.00
Other net29.73
Deferred Financing Costs-
Proceeds From Stock Options Early Exercised-
Proceeds From Issuance Of Common Stock Net Of Stock Issuance Costs-
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents35.67
Property Plant And Equipment Included In Accounts Payable-
Payments of Dividends, Preferred Stock and Preference Stock0.00
Dividends paid0.00
Net Cash Flow from Financing Activities65.58
Effect of exchange rate on cash flow0.21
Discontinued operations0.00
Free Cash Flow-85.97
Total Cash Flow-20.19
4 historic quarters locked

Sign in to unlock the full Immunic Inc cash flow history.

Sign In Create Free Account

About Immunic Inc Annual Cash Flow Statement

What this statement shows

This page presents issuer-reported cash flow data, including operating, investing, financing, net, and free cash flow, as disclosed in SEC 10-K filings and normalized by CSIMarket.

Source & verification

  • Form: 10-K (Period: 20251231)
  • Filed with the SEC: February 26, 2026
  • Source: imux-20251231.htm

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - normalization in the CSIMarket.com database.
  • Accession: 0001280776-26-000005

Figures are derived from filed reports and may be restated. Historical data is subject to revision.

Untitled Document 





                    


    



  Get the full CSIMarket dataset:
  Subscribe
  API
  License